The Cytochrome P450 Consortium

At a Glance
  • Status: Active Consortium
  • Year Launched: 2008
  • Initiating Organization: Molecular Discovery
  • Initiator Type: Industry
  • No disease focus
  • Location: International


The failure of promising drug candidates due to poor metabolic properties is incredibly costly for the pharmaceutical industry, as it typically follows many years of early-stage research. Given the strong background in this area, as demonstrated by the success of its MetaSite software, Molecular Discovery promoted the creation of the Cytochrome P450 Consortium, aimed at solving some of the most important problems in the predictive metabolism of potential drug candidates. The consortium will, for the first time, generate a large set of homogeneous experimental data for human metabolism, allowing the development of predictive in silico models; both the data and the models will be made available to all of the consortium members.


The main consortium goal is to produce high-quality and standardized experimental data (to guarantee homogeneity of the information) for several of the most relevant human cytochromes.


Points of Contact

Dr. Martin Bohl of Molecular Discovery
Tel: +49 171 174 11 61

Sponsors & Partners


Sanofi Aventis




Solvay Pharmaceuticals


Last Updated: 04/08/2016

The Consortia-pedia Catalogue is a living resource, and we are always adding new consortia. Provide information here about your collaboration to apply to be included in the Catalogue.

All the information contained in the Consortia-pedia was collected from publically available sources. Decisions to include or exclude a particular listing from Consortia-pedia were also made on the basis of publically available information and the criteria outlined in the FAQs. This site is intended to be an objective resource for the community, and inclusion does not constitute or imply endorsement, recommendation, or approval by FasterCures or the Milken Institute.